

Special Issue

CRISPR in Cancer Biology and Therapy: 2nd Edition

Message from the Guest Editor

Cancer is a disease of the genome, initiated by the activation of oncogenes and the inactivation of tumor suppressors. It is also a disease of the cell, feeding off changes in metabolism and motility and allowing cells to grow in different environments. Understanding how genomic changes drive the initiation of individual cancers is crucial for developing more effective treatment options and improving outcomes for patients with cancer. CRISPR has been utilized as a tool for programmable genome modifications in almost all cell types. The development of different CRISPR-mediated genome editing tools continues to drive major advances in the life sciences. In cancer research, CRISPR-related tools have greatly advanced our understanding of cancer genetics and tumor heterogeneity, providing new insights into therapeutic vulnerabilities. This Special Issue will focus on the development of CRISPR systems as a tool to study cancers, and the emerging adaptation of these technologies to improve diagnosis and treatment.

Guest Editor

Dr. Shun-Qing Liang

Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota Twin Cities, Phillips-Wangensteen Building RM 1-207, 516 Delaware Street SE, Minneapolis, MN 55455, USA

Deadline for manuscript submissions

29 August 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/218760

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)